Abstract
Recent years have seen progress in druggability simulations, that is, molecular
dynamics simulations of target proteins in solutions containing drug-like probe
molecules to characterize their drug-binding abilities, if any. An important consecu-
tive step is to analyze the trajectories to construct pharmacophore models (PMs) to
use for virtual screening of libraries of small molecules. While considerable success
has been observed in this type of computer-aided drug discovery, a systematic tool
encompassing multiple steps from druggability simulations to pharmacophore
modeling, to identifying hits by virtual screening of libraries of compounds, has
been lacking. We address this need here by developing a new tool, Pharmmaker,
building on the DruGUI module of our ProDy application programming interface.
Pharmmaker is composed of a suite of steps: (Step 1) identification of high affinity
residues for each probe molecule type; (Step 2) selecting high affinity residues and
hot spots in the vicinity of sites identified by DruGUI; (Step 3) ranking of the inter-
actions between high affinity residues and specific probes; (Step 4) obtaining probe
binding poses and corresponding protein conformations by collecting top-ranked
snapshots; and (Step 5) using those snapshots for constructing PMs. The PMs are
then used as filters for identifying hits in structure-based virtual screening.
Pharmmaker, accessible online at http://prody.csb.pitt.edu/pharmmaker, can be
used in conjunction with other tools available in ProDy.

KEYWORDS
druggability, molecular dynamics, pharmacophore modeling, target-based drug discovery, virtual
screening
aromatic, and charged regions) as well as shared geometric features (e.g., overall volume and shape and relative position of different types of chemical groups) of small molecules that are identified to be pharmacologically effective.\textsuperscript{6} Pharmaceutophore models can be built by ligand- or target-based methods. In the former case, the PM defines the common patterns of an ensemble of structurally aligned ligands known to have some desirable activity.\textsuperscript{7,12} A variety of software, such as HipHop,\textsuperscript{13} HypoGen,\textsuperscript{14} DISCO,\textsuperscript{15} GASP,\textsuperscript{16} PHASE,\textsuperscript{17} and PharmaGist\textsuperscript{1} have been developed to build PMs from ligands. Their performances mainly rely on their ability to handle the flexibility of ligands and their alignment. Ligand-based approaches have been used in developing inhibitors against Alzheimer’s disease,\textsuperscript{8} and targeting topoisomerase I,\textsuperscript{9} 17β-hydroxysteroid dehydrogenase 2,\textsuperscript{10} and CXC chemokine receptor 2.\textsuperscript{11} Ligand-based PMs require a set of ligands that are known to have well-defined pharmacological effects on a target protein or pathway, but the 3D structure of the target(s) is not required.

Target-based construction of PMs, on the other hand, takes account of the atomic interactions at the putative binding site of the target protein,\textsuperscript{18–23} and requires knowledge of the 3D structure of the target, or at least its ligand-binding pocket. Methods based on macromolecule-ligand complex structures, such as LigandScout,\textsuperscript{18} ZINCPharmer,\textsuperscript{24} Pharmit,\textsuperscript{25} and GBP\textsuperscript{26} can be used to build such PMs. Pharmacophore features are deduced from the geometry and interactions of the ligand bound to the target protein. However, the requirement of a structurally resolved complex with ligand limits the applicability of target-based pharmaceutophore modeling.

In view of the existence of structural data for target proteins and their homologs, macromolecule-based (without ligand) approaches such as GRID,\textsuperscript{27} SuperStar,\textsuperscript{28} HS-Pharm,\textsuperscript{19} Shaper\textsuperscript{29} Pocket V.3,\textsuperscript{30} and CavityPlus\textsuperscript{30} have been developed, which take as input the target structure only, to characterize the binding site. GRID uses an empirical force-field to evaluate the energy of probes at each grid point around the target structure, and determine the optimal poses at hot spots (positions that exhibit a high propensity to be occupied by ligands).\textsuperscript{21,27} SuperStar learns the distribution of probes from template molecules, and then uses a knowledge-based method to identify hot spots.\textsuperscript{28} HS-Pharm identifies hot spots using a machine learning method based on the fingerprints of known ligand-binding cavities.\textsuperscript{19} CavityPlus\textsuperscript{20} and Pocket V.3\textsuperscript{30} use CAVITY,\textsuperscript{31} a geometry-based program, to detect cavities and a grid-based method to define hot spots and assign scores. CavityPlus takes advantage of normal modes predicted by the Gaussian network model (GNM)\textsuperscript{31,32} to evaluate the potential allosteric effects of the druggable sites.\textsuperscript{33} All these tools consider atom–atom interactions and shape complementarity while entropic effects are often overlooked. The conformational entropy, and hence adaptability, of proteins to expose sites that are buried in the resolved structure has been a major motivation for developing flexible docking tools, as opposed to rigid docking.\textsuperscript{34–37} Yet, another entropic effect, associated with the frequency of binding a site, also plays a dominant role evidenced by the significance of evaluating probe clusters.\textsuperscript{24,38,39} Druggability simulations emerged as an approach that takes account of both types of entropies.

Druggability simulations are simply molecular dynamics (MD) simulations conducted in the presence of a solution containing probe molecules representative of drug-like fragments, to analyze their binding events onto the “moving” target (protein).\textsuperscript{40–45} These simulations demonstrate the ability of proteins to assume alternative conformations, expose potential binding cavities, and selectively bind specific types of probes. Statistical analysis of binding events sheds light onto both enthalpically and entropically favorable hot spots. Enthalpic effects are inferred from the strength/energy of ligand-protein interaction at the hot spots; entropic effects are deduced from the frequency of binding to a given hot spot. A notable study is that of Carlson and coworkers, where druggability simulations (called Mixed MD cosolvent simulations\textsuperscript{46}) were shown to successfully evaluate binding free energies and relative entropies for a series of allosteric proteins.\textsuperscript{47} Furthermore, coarse-grained models, such as the GNM\textsuperscript{31,32} and the anisotropic network model (ANM) provide unique analytic solutions for the ensemble of conformations sampled under equilibrium conditions,\textsuperscript{48} including potential allosteric changes,\textsuperscript{33} which can be advantageously utilized as input for conducting multiple runs. We have shown that druggability runs of ~40 ns can adequately identify orthosteric and allosteric sites.\textsuperscript{12,22,23,42,43,49} Equally important is the analysis of binding poses and residence times for different probes, which permit us to determine the composition of probes at the hot spots that are most likely to bind drug-like molecules and estimate the corresponding free energy of binding using simple Boltzmann statistics.\textsuperscript{33} While such analyses have been successfully performed for case studies, such as cytochrome c,\textsuperscript{22} γ-secretase,\textsuperscript{49} ionotropic glutamate receptors (iGluRs),\textsuperscript{42} PTP4A3 phosphatase,\textsuperscript{50} HIV-1 protease,\textsuperscript{51} K-Ras,\textsuperscript{52} and several allosteric proteins,\textsuperscript{47} a tool that complements the druggability simulations by systematic analysis of hot spots to construct PMs remains to be established.

Without an easy-to-use tool, the preparation of input files for druggability simulations and the analysis of the trajectories to retrieve information for further use in drug discovery requires a great deal of manual operations. Graham et al. developed a PyMOL plugin, Probeview, to facilitate such analyses.\textsuperscript{53} However, the tool does not handle the raw trajectories; instead it takes as input pre-calculated PDB files that contain occupancy information of grids. We developed DruGUL,\textsuperscript{43} a tool to assist in setting up druggability runs, that is, constructing input files for submitting runs to nanoscale molecular dynamics (NAMD),\textsuperscript{54} and to perform grid-based
analysis of the outputs and their visualization in visual molecular dynamics (VMD). The Mackerell lab also developed a tool called SILCS-Pharm for analyzing druggability simulations and extracting pharmacophore features from grid free energy fields called FragMaps. However, there is a need for a suite of tools that would further automate the analysis of trajectories and the characterization of probe-specific hot spots, to build PMs, and facilitate PM-based VS. We present here such a tool, Pharmmaker.

We present below the main features of Pharmmaker by way of application to a dimer of the main ligand-binding domain (LBD) of an AMPA receptor (AMPAR) paralogue GluA2 (PDB 1FTO), which we recently used in druggability simulations. AMPARs are glutamate-gated ion channels that are central to synaptic transmission and plasticity. The LBD binds the neurotransmitter glutamate, leading to conformational changes, initially at the monomer and dimer levels, which trigger receptor activation (opening of the downstream ion channel) and desensitization (entry into a long-lived agonist-bound closed channel state). This domain is also the main binding site for modulators such as cyclothiazide that bind at the dimer interface and block desensitization. The presence of multiple binding sites and the well-characterized dynamics of this domain make it suitable for benchmarking and illustrating our methodology.

2 | RESULTS

2.1 | Overview of Pharmmaker

Pharmmaker is a tool with a command-line interface, which takes outputs from druggability simulations package DruGUI as input, and constructs one or more PMs in a suitable format to be submitted to Pharmit. Key steps and corresponding outputs are presented below and schematically described in Figure 1. Also presented is a brief description of the preceding druggability analysis using DruGUI, as Step 1. Pharmmaker software and its tutorial can be downloaded from http://prody.csb.pitt.edu/tutorials/pharmmaker/.

2.2 | Step 1: Hot spots from druggability simulations

Step 1 is the identification of hot spots from druggability simulations using the DruGUI module implemented in ProDy, as described in our previous studies. In the present illustration, we include six probe molecules: isopropanol, acetamide, imidazole, acetate, isopropylamine, and isobutane (Figure 2a). The number and types of probe molecules can be modified by the user. Figure 2b shows a snapshot from our simulation box.
containing the target protein and the probe molecules in explicit water. Typically, the concentration of probe molecules is one probe for every 20 water molecules.

Figure 2c shows the results from DruGUI analysis where the spheres display probe-specific hot spots around the LBD dimer. The hot spots are color-coded as in panel A. Most of the hot spots are on the solvent-exposed surface of the target as the latter is easily accessible, but we also note a relatively buried site at the interface between the two monomers.

Figure 2d shows clusters of hot spots that are highly occupied by probes, which are predicted to serve as druggable sites. There are five druggable binding sites (labeled as Sites 1–5).

2.3 | Step 2: Identification of residues exhibiting high probe-specific affinities

In this step, we identify the residues that are involved in high affinity interactions with probes (Step 2 in Figure 1 and results in Figure 3a,b). To this aim, we assign a probe-specific binding score to each residue, and generate a binding profile as a function of residue index, for each probe type $p$. Figure 3, panels a and b, illustrate the six profiles, one for each probe, generated for subunits A and B, respectively. The probe-specific binding score of each residue $i$ is defined as $s(p, i) = \sum_{k=1}^{n} (1/d_{ik})^2$, where $k$ is each frame/snapshot index and $n$ is the total number of frames recorded during druggability simulations (in our case, 10,000 frames at intervals of 4 ps are recorded for each of the 40 ns runs), $i$ is residue index, and $d$ is the distance between contact-making heavy atoms belonging to the respective amino acid $i$ and probe $p$. Contact-making means that they are within
close proximity (4 Å) at a given frame. If a given residue-probe pair exhibits multiple atom-atom interactions in a snapshot, they are all included in the summation, thus accounting for the tight interaction. The binding score profiles permit us to identify the highest affinity residues by specifying a user-selected threshold score, above which residues are accepted to exhibit a high affinity for a specific probe. Data analysis shows that 500 Å⁻² (indicated by the dashed line in Figure 3a,b) is a good threshold for 40 ns runs. This analysis can be carried out using the command line program highaffresid.sh (see Supporting Information for details).

2.4 | Step 3: Selection of high-affinity residues located at druggable sites

The above analysis gives us information on high-affinity residues for specific types of probes. However, these may be isolated residues, which, in the absence of participation in a cluster of hot spots (or a druggable site) identified by DruGUI, might not stably bind drugs. Hence, we need to select the residues that participate in druggable sites (note that five were identified in Step 1). Therefore, we select from among the high affinity residues identified in Step 2, those that are located at the druggable sites (Step 3 in Figures 1 and 3c,d). Let us consider the highest affinity site (Site 1). This site exhibited high affinity for four different types of probes, isopropanol, acetamide, imidazole, and isobutane, shown in Figure 3c,d. Among the isopropanol-binding high affinity residues, for example, we select those within 8.0 Å from at least one of the three isopropanol hot spots at this site (yellow spheres in Figure 2d, lower part, also shown in Figure 3d left): P105, S108, L236, and N242 in subunit A and S108 in subunit B. Note that here, we use the residue numbering of the isolated LBD construct in the examined PDB structure, not that of the full receptor. Repeating the same procedure for each type of probe represented at Site 1, we obtain the four diagrams in Figure 3d, where the hot spots and corresponding high affinity residues are displayed for the four different probe types.

**FIGURE 3** High affinity residues of AMPAR GluA2 LBD dimer interacting with different types of probe molecules. (a, b) Binding score profiles for LBD subunits A (top) and B (bottom), evaluated for each type of probe molecule (curves in different colors, labeled). Binding score is as described in the text. Residues with score above 500 Å⁻² (see dashed line) are identified as high affinity residues for each type of probe. The residue numbers refer to those in the examined PDB file, corresponding to the isolated LBD. (c) Probe types and high affinity residues at the dimer interface. The corresponding hot spot positions for the probe types and potential coordinating residues are displayed in panel (d). Residues of subunit A are labeled in red, and those of chain B, in black. AMPAR, AMPA receptor; LBD, ligand-binding domain.
Selection of high affinity residues produces the outputs tabulated in Figure 3c. To generate this type of table in Pharmmaker, the outputs from the previous steps (hot spots from Step 1 and the high affinity residues from Step 2) are used. The high affinity residue files are found automatically, so this analysis can be carried out using the program siteselection.sh (see Supporting Information).

### 2.5 Step 4: Rank-ordering residue-probe interactions based on their frequency of occurrence

In this next step (Step 4 in Figures 1 and 4a,b), we focus on the residues selected in Step 3, and rank the corresponding residue-probe interactions based on their frequency of occurrence (entropy). This is achieved by simply counting the number of snapshots where the specific probe directly interacts with the selected high affinity residues. In the top-ranking case of P105(B)-isobutane, for example, there are six isobutane-specific hot spots (green spheres shown in Figures 2d, 3d, and 4b). First, we count the total number of snapshots where an isobutane probe is within 4 Å from the P105(B), based on heavy atoms. Then, we assign them to hot spots whose center is within 1.5 Å from any atom of the probe. We count the number of snapshots with a probe near this residue and occupying any of these six hot spots as shown in Figure 4b, which is 4,846 in this case, out of 10,000 snapshots per run of 40 ns, yielding a frequency of 0.4846. We repeat the procedure for each selected residue-probe pair. The resulting frequencies are rank-ordered and listed in Figure 4a. This analysis can be carried out using the program snapshotstatistics.sh, which takes the output from previous steps as inputs (see Supporting Information).

### 2.6 Step 5: Construction of a pharmacophore model

This is the final step in Pharmmaker (Step 5 in Figures 1, 4c, and 5a). We extract the snapshots that exhibit the most frequent interactions (the top 12 in Figure 4a using the frequency of occurrence 10% as default cutoff). We found a total of 13 snapshots that include these top 12 interactions. That is, all 13 snapshots display isobutane interacting with the residues P105(B), S108(B), S217(A), and K218(A); acetamide interacting with P105(B), N242(B), L239(B), K104(B), G219(A), and K218(B); and isopropanol interacting with N242(A) and P105(A). While the interactions could be made by different probes of the same type, it is also possible for only one probe to be interacting with multiple residues at the same time.

Figure 4c displays one such conformation representing a highly robust network of interactions, with side chains oriented to achieve optimal probe binding. The 13 snapshots/conformers that jointly display all the top-ranking
interactions are indeed quite similar structurally, with an average RMSD of 1.9 Å (see Figure S1a). These conformers are used as inputs for structure-based virtual screening in the next step. The use of probe poses and corresponding target conformations from the same snapshots allows us to obtain more accurate results. A specific target conformation is important in order to have accurate binding scores in virtual screening, for example, probe position and affinity are dependent on the side chains' rotameric states as well as the fluctuations in the backbone. This analysis can be carried out using the program snapshotstatistics.sh, which it takes the output from previous steps as inputs (see Supporting Information).

We use each of the snapshots selected in this step to construct a PM, as illustrated for one of the snapshots (numbered 761) in Figure 5a. The PM consists of two hydrophobic groups, one hydrogen bond acceptor and two hydrogen bond donors, arranged in a well-defined geometry, occupying a cavity (shown by the semi-transparent gray volume) at the interface between the two LBD protomers. It was created by selecting appropriate features based on the dominant interactions, which would then be realized in the next step.

2.7 | Step 6: Virtual screening of libraries of compounds using the PM

Figure 5 (Step 6, green box in Figure 1) shows the results from screening our PM against the ChEMBL database using the Pharmit Server. PM features were treated as...
spheres of 1 Å radius for matching against database compounds, and hits were filtered to only include 1 entry per compound and exclude compounds larger than 500 Da. This was then succeeded by minimization docking using AutoDock Vina within Pharmit, yielding the binding scores and hits shown in Figure 5b,c and Table 1 for snapshot 761. Other snapshots gave similar but distinct results as shown in Figure S1b, S2, and Table S1. We therefore recommend users to use all the snapshots containing the most dominant interactions and compare them. While the global interactions are maintained throughout the simulation, the exact conformation will likely change over time, allowing them to sample more possible binders. It should, however, be noted that after a certain degree of conformational change, DruGUI analysis results may not be meaningful when carried out over a whole trajectory, which is why we use 40 ns.

Figure 5c lists the top-ranking compounds (hits) from VS, and the corresponding AutoDock Vina scores (or binding energies) and RMSDs with respect to the pharmacophore features after energy minimization (mRMSD). We note that a score below −10 kcal/mol represents a highly favorable (nanomolar range) interaction. The poses of the top five compounds are shown in blue sticks in Figures 5d and S3a, along with the poses of known allosteric modulators in red, a benzothiadiazine, designated as compound 11m (PDB id: 5OEW; also shown in Figure 5e), and the biarylpolsulfonamides (R,R)-2a (PDB id: 3BBR), and (R,R)-2b (PDB id: 4USB) (see Figure S3b for individual examples). Therefore, the hits occupy the same space as the known allosteric modulator, and exhibit similar features as illustrated in panels d and e of Figure 5. It remains to be experimentally tested and verified whether these compounds could function as well or even better than the existing modulators.

The screening against ChEMBL also allowed us to identify some experimentally verified compounds with good scores (see Figure 5b,e, S3c, Table 1). The best one (first row of Table 1) corresponds to the compound 11m mentioned above and the predicted binding pose matches the known one in the resolved structure (PDB id: 5OEW) very well (Figure 5e). Interestingly, these compounds show small RMSDs (< 1.0 Å) with respect to the PM before minimization docking (Table 1) and, in some cases, the binding scores after docking correlate very well with the inferred binding affinity from functional experiments (pEC50 in Table 1). The compound 11m is likely the most potent AMPAR modulator to date with an effective concentration for 50% activity (EC50) of 2.0 nM, corresponding to a pEC50 (−log10 EC50) of 8.700 in line with the binding score of −8.34 kcal/mol. Another compound in the same series (known compound #3; Figure S3c) has a pEC50 of 7.336 and a binding score of −7.44 kcal/mol. Therefore, the new compounds predicted by our method have the potential to bind with sub-nanomolar affinity.

### 3 CONCLUSION

Structure-based VS is not easy, especially if there is no information about binding pocket, binding features, and poses; and target flexibility makes it an even more challenging problem. A strong aspect of our method is that it uses multiple target conformations dependent on the binding poses of probes where they interact during druggability simulations. Therefore, the binding score in VS can be more evaluated in a more realistic manner. Also, we can have multiple PMs for the same site, with different target conformations and probe poses, which can be analyzed statistically. Furthermore, multiple different compositions of PM features can be explored. In this article, we focused on the highest affinity site, which is a known allosteric site, but we can focus on other sites that harbor clusters of hot spots and on specific residues if necessary. Our method is purely computational and unbiased, and we believe that this new tool will assist in current efforts in drug discovery and development, especially in the identification of allosteric modulators.

| Compound (ChEMBL ID) | pEC50a | Initial RMSD (Å) | Binding energy (kcal/mol) | RMSD after minimization (mRMSD; Å) | Rank among all compoundsb | Rank among known compoundsb |
|----------------------|--------|------------------|--------------------------|----------------------------------|--------------------------|--------------------------|
| CHEMBL4091984        | 8.700  | 0.57             | −8.34                    | 1.63                             | 1,159                    | 1                        |
| CHEMBL1214203        | 5.100  | 0.56             | −7.70                    | 2.75                             | 2,957                    | 2                        |
| CHEMBL4060993        | 7.336  | 0.65             | −7.44                    | 1.21                             | 4,001                    | 3                        |
| CHEMBL1290503        | 5.398  | 0.60             | −6.97                    | 2.77                             | 6,297                    | 4                        |
| CHEMBL1277180        | 5.796  | 0.70             | −6.72                    | 2.30                             | 7,645                    | 5                        |
| CHEMBL1214334        | 5.900  | 0.75             | −6.57                    | 2.26                             | 8,452                    | 6                        |

aExtracted from the cited articles, or calculated as −log10(EC50).

bAfter minimization.
4 | METHODS

The manuscript is a tool description overall. So, we present below a brief overview only, and more details including all intermediate steps, commands, and quantitative data, are provided in the Supporting Information and in the Tutorial accessible online.

Druggability simulations and trajectory analyses were performed as described previously. Briefly, simulations were run using the probe set shown in Figure 2 (selected as representatives of drug fragments with different physicochemical properties) using the molecular dynamics (MD) simulation package NAMD with the CHARMM22 force field for proteins, the TIP3P water model, and the CGenFF force field (version 43) for the probes. Trajectory analyses were performed using the DruGUI module of ProDy. The target protein used for illustration of Pharmaker is AMPAR GluA2 LBD dimer (PDB id: 1FTO). Two independent runs were performed for AMPAR GluA2 LBD dimer, which yielded similar results in DruGUI analysis, in agreement with experiments. We use one of them here for illustrative purposes. The latter presented five druggable sites. We focused on the highest affinity site indicated by DruGUI analysis, which agreed well with experiments. All MD snapshots were superposed onto the reference PDB structure using Cα-atoms and a cubic grid-based representation of the space was used for the analysis. Grid edge size was set to 0.5 Å. Probe molecules having non-hydrogen atoms within 2.5 Å from protein atoms were considered to interact with the protein. For each probe type, the individual occupancy of grids was calculated using their centroids. We evaluated the occupancy of each probe for a given voxel. High occupancy voxels, called hot spots, within a distance less than 5.5 Å were merged and druggable sites were defined by clusters of at least six such hot spots. We obtained five druggable sites as shown in Figure 2d; details of binding affinity calculations are explained in the Supporting Information. The druggable sites were analyzed further to build a PM with our new tool called Pharmmaker, written in Tcl and Bash. This tool is described in our results section and outlined in Figure 1. Details of each step are described in the Supporting Information, and the tutorial files are accessible online at http://prody.csb.pitt.edu/tutorials/pharmaker.

We used Pharmit, which is for VS of large compound databases using pharmacophore features, molecular shape, and energy minimization. We applied the following filters: 1 hit per molecule and molecular weight ≤ 500. Features as described in the results were used for screening the ChEMBL database. Data visualization are performed using ProDy 1.10.10, VMD 1.9.1, and PyMOL 1.8.6.

ACKNOWLEDGMENT

Support from the National Institutes of Health Grants P30DA035778 and P41GM103712 are gratefully acknowledged by IB. We also thank Dr. David Koes for useful discussions about Pharmit.

ORCID

Ivet Bahar https://orcid.org/0000-0001-9959-4176

REFERENCES

1. Leach AR, Gillet VJ, Lewis RA, Taylor R. Three-dimensional pharmacophore methods in drug discovery. J Med Chem. 2010;53:539–558.
2. Chen Z, Li HL, Zhang QJ, et al. Pharmacophore-based virtual screening versus docking-based virtual screening: A benchmark comparison against eight targets. Acta Pharmacol Sin. 2009;30:1694–1708.
3. Evanthia L, George S, Demetrios KV, Zoe C. Structure-based virtual screening for drug discovery: Principles, applications and recent advances. Curr Top Med Chem. 2014;14:1923–1938.
4. Yu W, MackeRell AD Jr. Computer-aided drug design methods. Methods Mol Biol. 2017;1520:85–106.
5. Lo Y-C, Rensi SE, Tong W, Altman RB. Machine learning in chemoinformatics and drug discovery. Drug Discov Today. 2018;23:1538–1546.
6. Yang S-Y. Pharmacophore modeling and applications in drug discovery: Challenges and recent advances. Drug Discov Today. 2010;15:444–450.
7. Schneidman-Duhovny D, Dror O, Inbar Y, Nussinov R, Wolfson HJ. PharmaGist: A webserver for ligand-based pharmacophore detection. Nucleic Acids Res. 2008;36:W223–W228.
8. Dhanjal JK, Sharma S, Grover A, Das A. Use of ligand-based pharmacophore modeling and docking approach to find novel acetylcholinesterase inhibitors for treating Alzheimer’s. Biomed Pharmacother. 2015;71:146–152.
9. Pal S, Kumar V, Kundu B, et al. Ligand-based pharmacophore modeling, virtual screening and molecular docking studies for discovery of potential topoisomerase I inhibitors. Comput Struct Biotechnol J. 2019;17:291–310.
10. Vuorinen A, Engeli R, Meyer A, et al. Ligand-based pharmacophore modeling and virtual screening for the discovery of novel 17β-hydroxysteroid dehydrogenase 2 inhibitors. J Med Chem. 2014;57:5995–6007.
11. Che J, Wang Z, Sheng H, et al. Ligand-based pharmacophore model for the discovery of novel CXCR2 antagonists as anticancer metastatic agents. R Soc Open Sci. 2018;5:180176.
12. Mustata G, Follis AV, Hammoudeh DI, et al. Discovery of novel Mycz–Max heterodimer disruptors with a three-dimensional pharmacophore model. J Med Chem. 2009;52:1247–1250.
13. Barnum D, Greene J, Smellie A, Sprague P. Identification of common functional configurations among molecules. J Chem Inf Comput Sci. 1996;36:563–571.
14. Li H, Sutter J, Hoffmann R. HypoGen. An automated system of generating 3D predictive pharmacophore models. In: Güner OF, editor.
Pharmacophore perception, development, and use in drug design. La Jolla, Calif: International University Line, 2000; p. 171–189.

15. Martin YC. DISCO: What we did right and what we missed. In: Güner OF, editor. Pharmacophore perception development and use in drug design. La Jolla, CA: International University Line, 2000.

16. Jones G, Willet P. GASP: genetic algorithm superimposition program. Pharmacophore perception develop use drug design. La Jolla, CA: International University Line, pp 85–106.

17. Dixon SL, Smondyrev AM, Knoll EH, Rao SN, Shaw DE, Friesner RA. PHASE: A new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results. J Comput Aided Mol Des. 2006;20:647–671.

18. Wolber G, Langer T. LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters. J Chem Inf Model. 2005;45:160–169.

19. Barillari C, Marcou G, Rognan D. Hot-spots-guided receptor-based pharmacophores (HS-pharm): A knowledge-based approach to identify ligand-anchoring atoms in protein cavities and prioritize structure-based pharmacophores. J Chem Inf Model. 2008;48:1396–1410.

20. Xu Y, Wang S, Hu Q, et al. CavityPlus: A web server for protein cavity detection with pharmacophore modelling, allosteric site identification and covalent ligand binding ability prediction. Nucleic Acids Res. 2018;46:W374–W379.

21. Tintori C, Corradi V, Magnani M, Manetti F, Botta M. Targets looking for drugs: A multistep computational protocol for the development of structure-based pharmacophores and their applications for hit discovery. J Chem Inf Model. 2008;48:2166–2179.

22. Bakan A, Kapralov AA, Bayir H, Hu F, Kagan VE, Bahar I. Inhibition of peroxidase activity of cytochrome c: de novo compound discovery and validation. Mol Pharmacol. 2015;88:421–427.

23. Mustata G, Li M, Zevola N, et al. Development of small-molecule PUMA inhibitors for mitigating radiation-induced cell death. Curr Top Med Chem. 2011;11:281–290.

24. Koes DR, Camacho CJ. ZINCPharmer: Pharmacophore search of the ZINC database. Nucleic Acids Res. 2012;40:W409–W414.

25. Sunseri J, Koes DR. Pharmit: Interactive exploration of chemical space. Nucleic Acids Res. 2016;44:W442–W448.

26. Ortuso F, Langer T, Alcaro S. GBPM: GRID-based pharmacophore model: Concept and application studies to protein–protein recognition. Bioinformatics. 2006;22:1449–1455.

27. Goodford PJ. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J Med Chem. 1985;28:849–857.

28. Verdronk ML, Cole JC, Taylor R. SuperStar: A knowledge-based approach for identifying interaction sites in proteins. J Mol Biol. 1999;289:1093–1108.

29. Tran-Nguyen V-K, Da Silva F, Bret G, Rognan D. All in one: Cavity detection, druggability estimate, cavity-based pharmacophore perception, and virtual screening. J Chem Inf Model. 2019;59:573–585.

30. Jing C, Xiaomin M, Yaxia Y, Jianfeng P, Luhua L. Protein-protein interface analysis and hot spots identification for chemical ligand design. Curr Pharma Des. 2014;20:1192–1200.

31. Yaxia Y, Jianfeng P, Luhua L. Binding site detection and druggability prediction of protein targets for structure-based drug design. Curr Pharma Des. 2013;19:2326–2333.

32. Li H, Chang Y-Y, Yang L-W, Bahar I. iGNM 2.0: The Gaussian network model database for biomolecular structural dynamics. Nucleic Acids Res. 2015;44:D415–D422.

33. Ma X, Meng H, Lai L. Motions of allosteric and orthosteric ligand-binding sites in proteins are highly correlated. J Chem Inf Model. 2016;56:1725–1733.

34. Cavasotto CN, Abagyan RA. Protein flexibility in ligand docking and virtual screening to protein kinases. J Mol Biol. 2004;337:209–225.

35. Floquet N, Marechal J-D, Badet-Denisot M-A, Robert CH, Dauchez M, Perahia D. Normal mode analysis as a prerequisite for drug design: Application to matrix metalloproteinases inhibitors. FEBS Lett. 2006;580:5130–5136.

36. May A, Zacharias M. Protein–ligand docking accounting for receptor side chain and global flexibility in normal modes: Evaluation on kinase inhibitor cross docking. J Med Chem. 2008;51:3499–3506.

37. Loving KA, Lin A, Cheng AC. Structure-based druggability assessment of the mammalian structural proteome with inclusion of light protein flexibility. PLoS Comp Biol. 2014;10:e1003741.

38. Hall DR, Kozakov D, Whitty A, Vajda S. Lessons from hot spot analysis for fragment-based drug discovery. Trends Pharmacol Sci. 2015;36:724–736.

39. Wakefield AE, Mason JS, Vajda S, Keserü GM. Analysis of tractable allosteric sites in G protein-coupled receptors. Sci Rep. 2019;9:6180.

40. Seco J, Luque FJ, Barril X. Binding site detection and druggability index from first principles. J Med Chem. 2009;52:2363–2371.

41. Iveta A, McCammon JA. Mapping the druggable allosteric space of G-protein coupled receptors: A fragment-based molecular dynamics approach. Chem Biol Drug Des. 2010;76:201–217.

42. Lee JY, Krieger J, Herguedas B, et al. Duggrability simulations and X-ray crystallography reveal a ligand-binding site in the GluA3 AMPA receptor N-terminal domain. Structure. 2019;27:241–252.

43. Bakan A, Nevins N, Lakdawala AS, Bahar I. Druggability assessment of allosteric proteins by dynamics simulations in the presence of probe molecules. J Chem Theory Comput. 2012;8:2435–2447.

44. Guvensch O, Mackrell AD Jr. Computational fragment-based binding site identification by ligand competitive saturation. PLoS Comput Biol. 2009;5:e1000435.

45. Raman EP, Yu W, Lakkaraju SK, Mackrell AD Jr. Inclusion of multiple fragment types in the site identification by ligand competitive saturation (SILCS) approach. J Chem Inf Model. 2013;53:3384–3398.

46. Ghnakotra P, Carlson HA. Moving beyond active-site detection: MixMD applied to allosteric systems. J Phys Chem B. 2016;120:8685–8695.

47. Ghnakotra P, DasGupta D, Carlson HA. Free energies and entropies of binding sites identified by MixMD cosolvent simulations. J Chem Inform Mod. 2019;59:2035–2045.

48. Bakan A, Meireles LM, Bahar I, ProDy: Protein dynamics inferred from theory and experiments. Bioinformatics. 2011;27:1575–1577.

49. Lee JY, Feng Z, Xie X-Q, Bahar I. Allosteric modulation of intact γ-secretase structural dynamics. Biophys J. 2017;113:2634–2649.

50. Sharlow ER, Wipf P, McQueeney KE, Bakan A, Lazo JS. Investigational inhibitors of PTP4A3 phosphatase as antineoplastic agents. Expert Opin Investig Drugs. 2014;23:661–673.
51. Ung PMU, Ghanakota P, Graham SE, Lexa KW, Carlson HA. Identifying binding hot spots on protein surfaces by mixed-solvent molecular dynamics: HIV-1 protease as a test case. Biopolymers. 2016;105:21–34.

52. Prakash P, Hancock JF, Gorfe AA. Binding hotspots on K-ras: Consensus ligand binding sites and other reactive regions from probe-based molecular dynamics analysis. Proteins. 2015;83:898–909.

53. Graham SE, Leja N, Carlson HA. MixMD Probeview: Robust binding site prediction from cosolvent simulations. J Chem Inf Model. 2018;58:1426–1433.

54. Phillips JC, Braun R, Wang W, et al. Scalable molecular dynamics with NAMD. J Comput Chem. 2005;26:1781–1802.

55. Humphrey W, Dalke A, Schulten K. VMD: Visual molecular dynamics. J Mol Graph. 1996;14:27–38.

56. Yu W, Lakkaraju SK, Raman EP, Fang L, MacKerell AD Jr. Mechanisms of postsynaptic localization of AMPA-type glutamate receptors and their regulation during long-term potentiation. Sci Signal. 2019;12(ear689).

57. Traynelis SF, Wollmuth LP, Mcbain CJ, et al. Glutamate receptor ion channels: Structure, regulation, and function. Pharm Rev. 2010;62:405–496.

58. Armstrong N, Gouaux E. Mechanisms for activation and antagonism of an AMPA-sensitive glutamate receptor: Crystal structures of the GluR2 ligand binding core. Neuron. 2000;28:165–181.

59. Buonarati OR, Hammes EA, Watson JF, Greger IH, Hell JW. Mechanisms of postsynaptic localization of AMPA-type glutamate receptors and their regulation during long-term potentiation. Sci Signal. 2019;12:ear689.

60. Sun Y, Olson R, Horning M, Armstrong N, Mayer M, Gouaux E. Mechanism of glutamate receptor desensitization. Nature. 2002;417:245–253.

61. Armstrong N, Jasti J, Beich-Frandsen M, Gouaux E. Measurement of conformational changes accompanying desensitization in an ionotropic glutamate receptor. Cell. 2006;127:85–97.

62. Chen S, Zhao Y, Wang Y, Shekhar M, Tjakhorshid E, Gouaux E. Activation and desensitization mechanism of AMPA receptor-TARP complex by cryo-EM. Cell. 2017;170:1234–1246.

63. Kumar J, Mayer ML. Functional insights from glutamate receptor ion channel structures. Annu Rev Physiol. 2013;75:313–337.

64. Sun Y, Olson R, Horning M, Armstrong N, Mayer M, Gouaux E. Mechanism of glutamate receptor desensitization. Nature. 2002;417:245–253.

65. Twomey EC, Yelshanskaya MV, Grassucci RA, Frank J, Sobolevsky AL. Structural bases of desensitization in AMPA receptor-auxiliary subunit complexes. Neuron. 2017;94:569–580.

66. Twomey EC, Yelshanskaya MV, Grassucci RA, Frank J, Sobolevsky AL. Channel opening and gating mechanism in AMPA-subtype glutamate receptors. Nature. 2017;549:60–65.

67. Partin KM. AMPA receptor potentiators: From drug design to cognitive enhancement. Curr Opin Pharmacol. 2015;20:46–53.

68. Gaulton A, Hersey A, Nowotka M, et al. The ChEMBL database in 2017. Nucleic Acids Res. 2017;45:D945–D954.

69. Sterling T, Irwin JJ. ZINC 15 – Ligand discovery for everyone. J Chem Inf Model. 2015;55:2324–2337.

70. Koes DR, Baumgartner MP, Camacho CJ. Lessons learned in empirical scoring with smina from the CSAR 2011 benchmarking exercise. J Chem Inf Model. 2013;53:1893–1904.

71. Trott O, Olson AJ. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31:455–461.

72. Goffin E, Drapier T, Larsen AP, et al. 7-phenoxy-substituted 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxides as positive allosteric modulators of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors with nanomolar potency. J Med Chem. 2018;61:251–264.

73. Kaae BH, Harpsoe K, Kastrup JS, et al. Structural proof of a dimeric positive modulator bridging two identical AMPA receptor-binding sites. Chem Biol. 2007;14:1294–1303.

74. Chen L, Durr KL, Gouaux E. X-ray structures of AMPA receptor-cone snail toxin complexes illuminate activation mechanism. Science. 2014;345:1021–1026.

75. Mackerell AD Jr, Feig M, Brooks CL 3rd. Extending the treatment of backbone energetics in protein force fields: Limitations of gas-phase quantum mechanics in reproducing protein conformational distributions in molecular dynamics simulations. J Comput Chem. 2004;25:1400–1415.

76. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML. Comparison of simple potential functions for simulating liquid water. J Chem Phys. 1983;79:926–935.

77. Vanommeslaeghe K, Mackerell AD Jr. CHARMM additive and polarizable force fields for biophysics and computer-aided drug design. Biochim Biophys Acta. 2015;1850:861–871.

78. Bakan A, Dutta A, Mao W, et al. Evol and Prody for bridging protein sequence evolution and structural dynamics. Bioinformatics. 2014;30:2681–2683.

79. Schrodinger L. The PyMOL Molecular Graphics System, Version 1.8.4.2. (2016).

80. Ward SE, Harries M, Aldegheri L, et al. Discovery of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide, a novel clinical AMPA receptor positive modulator. J Med Chem. 2010;53:5801–5812.

81. Theuwis KM, Aldegheri L, Harries MH, Mookherjee C, Oliosi B, Ward SE. N-substituted pyrrolidines and tetrahydrofurans as novel AMPAR positive modulators. Bioorg Med Chem Lett. 2010;20:7116–7119.

82. Grove SJ, Jamieson C, Maclean JK, Morrow JA, Rankovic Z. Positive allosteric modulators of the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor. J Med Chem. 2010;53:7271–7279.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section at the end of this article.